EP0098853A1 - A pharmaceutical composition for preventing and treating ischemic cell damage and methods for the use and preparation thereof - Google Patents
A pharmaceutical composition for preventing and treating ischemic cell damage and methods for the use and preparation thereofInfo
- Publication number
- EP0098853A1 EP0098853A1 EP83900363A EP83900363A EP0098853A1 EP 0098853 A1 EP0098853 A1 EP 0098853A1 EP 83900363 A EP83900363 A EP 83900363A EP 83900363 A EP83900363 A EP 83900363A EP 0098853 A1 EP0098853 A1 EP 0098853A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical composition
- physiologically acceptable
- preventing
- solution
- cell damage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Abstract
Une composition pharmaceutique permettant la prévention et le traitement de dégâts cellulaires ischémiques contient un sel soluble dans l'eau, physiologiquement acceptable d'acide phosphoénolpyruvique et un sel soluble dans l'eau physiologiquement acceptable de l'acide adénosine-5'-triphosphorique dans un rapport mutuel de 5:1 à 1000:1, de préférence de 10:1 à 500:1, calculé sur une base molaire. Un procédé de prévention et de traitement de dégâts cellulaires ischémiques par administration d'une telle composition est également décrit ainsi qu'un procédé de préparation de cette composition par dissolution de ces sels dans un liquide aqueux physiologiquement acceptable, ajustement de la valeur du pH de la solution, stérilisation et, si besoin est, lyophilisation.A pharmaceutical composition for preventing and treating ischemic cell damage contains a physiologically acceptable water-soluble salt of phosphoenolpyruvic acid and a physiologically acceptable water-soluble salt of adenosine-5'-triphosphoric acid in a mutual ratio of 5: 1 to 1000: 1, preferably from 10: 1 to 500: 1, calculated on a molar basis. A method for preventing and treating ischemic cell damage by administration of such a composition is also described, as well as a method for preparing this composition by dissolving these salts in a physiologically acceptable aqueous liquid, adjusting the pH value of the solution, sterilization and, if necessary, lyophilization.
Description
A PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ISCHEMIC CELL DAMAGE AND METHODS FOR THE USE AND PREPARATION THEREOF
The present invention relates to a pharmaceutical composition. More specificly, the invention relates to a pharmaceutical composition for preventing and treating ischemic cell damage. The invention also relates to a method for preventing and treating ischemic cell damage in mammals, including humans, or in organs removed therefrom.
Ischemic damage to the body cells of a mammal occurs when the flow of blood in a part of the body is impeded to such an extent that the supply of oxygen to the cells of said part of the body ceases or is greatly reduced. The reason why the cell requires oxygen is because the predominant part (about 92 % ) of adenosine-5'-triphosphate (ATP), necessary to the survival of the cell, is formed by a mechanism which involves an aerobic oxida-tion. In the event of an oxygen deficiency, the ATP-content of the cell falls, the resultant injury to the cell being initially reversible, i.e. the damage can be stopped when the ATP content of the cell returns to more normal values, and in time becomes irreversible, resulting in the death of the cell and subsequently (with an increase in the number of dead cells) the death of the organ.
In order to reduce the extent of ischemic cell damage, it is feasible to think that the ATP-content of the cells could be increased by supplying ATP directly to the cells, thereby to avoid the aerobic forming reaction for ATP. It has been found, however, that exogenous ATP cannot penetrate into the cells to the extent required to markedly ease the ischemic damage.
In accordance with the present invention it has now surprisingly been found that an introduction of relatively small quantities of ATP enables another substance, namely a salt of phosphoenolpyruvic acid, to be introduced into the cell in larger quantities simultaneously with ATP, where said substance then contributes to the conversion of adenosine
diphosphate (ADP) present in the cell to ATP in one single reaction step which does not require the presence of oxygen.
Accordingly, the present invention relates to a pharmaceutical composition for preventing and treating ischemic cell damage, said composition being characterized in that it includes a physiologically acceptable, watersoluble salt of phosphoenolpyruvic acid (which salt is hereinafter referred to as PEP) and a physiologically acceptable, water-soluble salt of adenosine-5'-triphosphoric acid (which salt. is hereinafter referred to as ATP) in a mutual ratio of 5:1 to 1000:1, preferably from 10:1 to 500:1, calculated on a molar basis.
As examples of physiologically acceptable salts of the two compounds can be mentioned sodium salts, magnesium salts or ammonium salts and salts with physiologically acceptable organic amines, such as tris(hydroxymethyl)aminomethane (called tris), methyl glucamine, arginine, ornitine or histidirie.
Conveniently, the molar ratio between PEP and ATP can, for example, be greater than 20:1, for example greater than 50:1, and can be lower than 400:1, e.g. lower than 300:1, e.g. lower than 200:1.
With the composition according to the invention there is obtained with the two incorporated components a synergistic effect. This effect cannot be obtained with solely one of the components. Neither can such an advantageous effect, free from complications, be obtained with PEP in combination with other additives.
In addition to the salts of phosphoenolpyruvic acid and of adenosine-5'-triphosphoric acid the pharmaceutical composition according to the invention comprises agents for establishing physiological conditions and, when necessary, water as a carrier.
For the purpose of administration, the composition according to the invention is in the form of a sterile solution for parenteral administration and organ perfusion, but is preferably stored in a freeze-dried form because of the unfavourable stability properties of the solutions.
Agents for establishing physiological conditions are, for instance, buffer substances, ions for establishing correct osmolality and, when necessary, colloid-osmotically active substances, such as albumin and clinical dextrans, e.g. Dextran 40.
p hysiological saline solution, whereafter the pH of the solu ti on is adjusted as necessary with the aid of a base or an acid (which will provide physiologically acceptable salts) to obtain a physiologically acceptable pH (which is selected in dependence upon quantity and area of application, for example within the pH-range of 3 - 7.6, such as 4 - 7). Subsequent to being sterilized, e.g. by sterile filtration, th e
e.g. a physiologically acceptable salt solution or buffer solution, such as a phosphate buffer solution or an infusion solution of conventional composition .
The pH can be adjusted with the use of bases or acids which provide physiologically acceptable salts, e.g. inorganic bases, preferably alkaline metal hydroxides, such as sodium hydroxide or potassium hydroxide, or organic bases, e.g. basic amino acids, such as arginine or ornitine or tris or methyl gl ucamine or histidine or..inorganic acids, such as HCl or organic acids, such as acetic acid.
tion hereto in accordance with the aforegiven molar stoichi ometric rel ationshi ps .
In accordance with a further method of preparation, a sterile PEP and ATP in solid state (e.g. in freeze-dried form) are dry-mixed in the aforegiven mutual quantity ratio, whereafter the mixture is conveniently pre-packed in dosage units, such as bottles containing a quantity of the mixture corresponding to a normal dose. Prior to being used, a dosage quantity of the mixture is then dissolved in a given volume of a sterile, physiologically acceptable aqueous liquid, e.g. an isotonic buffer solution, such as a tris buffer solution or a phosphate buffer solution.
In accordance with one embodiment of the invention, the composition may also contain magnesium ions, for example in a stoichiometric relationship of about 1:1 in relation to ATP. These ions may be supplied, for example, by introducing a physiologically acceptable magnesium salt, preferably MgCl2, in a measured quantity at a suitable stage in the preparation process, e.g. added to a buffer solution in which a powderous mixture of PEP and ATP is dissolved, or by dissolving the magnesium salt in a physrόl δgtcally isotonic saline solution in conjunction with dissolving PEP and ATP therein.
The composition according to the invention is administered in the form of a sterile solution for parenteral administration and organ perfusion, to prevent and treat ischemic cell damage (preferably in humans but also in other mammals). An important area of application for the composition according to the invention is its use as a perfusion and preservation solution for organs, e.g. in open heart surgery, and organ transplantations. Another important area of application is the use of the composition as an infusion solution for directed infusion through cathethers for treating ischemic brain and heart damage as result of. heart failure, drowning, an overdose of certain types of pharmaceutical preparations, such as soporifics etc.
The active substance concentration of the solutions intended for administration varies in dependence upon the distance from the site at which the solutions are administered to the location of the ischemic cell damage to be treated. Suitably, the concentration of the solution at the location of application remote from the location of the damage is such as to achieve an extracellular concentration of ATP at the injured location of an order of magnitude of 1 - 4 % , preferably 2 - 3 %, of the intracellular physiological concentration of ATP in the body cells. This means, for examnle, in the case of perfusion solutions and preservation solutions that the concentration of such solutions with respect to PEP should be such that the organ (e.g. a heart) obtains during the whole of the perfusion period a total of, for example, 20 - 60 mmoles PEP. If the total perfusion volume is calculated to be one litre, the solution may contain for example 20 - 60 mmoles PEP per litre. If the solution volume totals two litres, the solution may correspondingly contain 10 - 30 mmoles PEP per litre. The amount of ATP is selected in relation to the amount of PEP, so as to obtain the aforegiven mutual molar relationship.
When treating ischemic cell damage in organs by infusion, the dosage may be, for example, 0.1-2, e.g. 0.5-1, mmole PEP per kilo body weight, the amount of ATP being selected in relation to the amount of PEP so as to fulfil the aforegiven molar stoi chi ometry. For example, in the case of a directed dosing of PEP of 1 mmole/kilo body weight to a patient weighing 75 kilos, said patient obtains a total of 75 mmoles PEP (and ATP in relation thereto). This can be administered with a 50 ml solution, the PEP concentration of which is 1500 mmoles per litre. With respect to infusion solutions for directed infusion through catheters, a higher concentration is suitably selected, to compensate for dilution and losses from the infusion site to the target organ.
Thus, the amounts, in which the composition according to the invention is administered will vary with the area of
application.
The invention also relates to a method of preventing and treating ischemic cell damage in mammals, including humans, or in organs removed therefrom, the method being characterized by supplying to the mammal or to the organ a therapeutically effective dose of a pharmaceutical composition according to the invention.
The invention will now be desribed in more detail with reference to a number of examples.
EXAMPLE 1
1.6 mmole monosodium phosphoenol pyruvate and 0.01 mmole disodiumadenosi ne-5'-triphosphate are dissolved, while stirring, in 100 ml of a physiological saline solution (0.9 g NaCl/ 100 ml), whereafter the pH of the solution is ad- justed to 6.4 - 7.0 by adding dropwise to said solution
1 N and 0.1 N sodium hydroxide solution. The resultant solution is sterilized by sterile filtration, poured into 20 ml bottles and lyophilized, whereafter the bottles are sealed (all under aseptic conditions). Subsequent to dissolving the content of one bottle in a physiological aqueous solution, the resultant composition is suited for organ perfusion in experiments on rats.
EXAMPLE 2 The procedure described in Example 1 is followed but with 400 mmoles of monosodium phosphoenolpyruvate and 4 mmoles of di sodium-adenosi ne-5'-triphosphate.
Subsequent to dissolving the contents of one bottle in a physiological aqueous solution, the resultant composition is suitable for human use with directed infusion. PHARMACOLOGICAL
EXPERIMENTS
For these experiments there was used a model comprising an excised rat heart, substantially in accordance with
Gamble et al., Am. J. Physiol. 219 : 604612 (1970) although modified so that the abdominal aorta of the supporting rat was connected directly to the ascending aorta of the excised
heart in accordance with the following:
Unstarved male Sprague-Dawl ey-rats weighing about 300 g were used in the experiment.
The ascending aorta of an excised rat heart was connec ted to the abdominal aorta of a living rat ("supporting rat") functioning as a heart-lung-machine for the excised rat heart by means of a tube ("pump tube"). The coronary effluent from the excised heart was collected in a tempera ted water- jacketed funnel and retransfused to the supporting rat. After the ischemic period, a pulsatile blood flow was established from the supporting rat to the excised heart. The temperature of th± supporting rat and the excised rat heart was kept at 37° ± 1°C.
Rats intended for supporting function were anaesthetized by intraperi toneal administration of 5-sec.-butyl-5-ethyl 2-thiobarbituric acid (Inactin ® from Byk-Gulden Lomberg Chem. Fabrik GmbH, Konstanz, West Germany) 120 mg per kilo body weight. After tracheostomy the right carotis communis was cannulated for continuous blood pressure recording by an EMT 34 transducer (from Siemens-Elema AB, Solna, Sweden) and an M 34 recorder (from Siemens-Elema AB, Solna, Sweden). The right jugular vein was cannulated for transfusion. Heparin in a dose of 200 IU (international units) was administred intravenously. The supporting rat breathed air spontaneously.
The abdominal aorta was cannulated and the cannula was fixed to the aorta by silk ligatures. The cannula was cut close to the aorta and rejoined by a more flexible piece of si 1 icone rubber tubing, to permit easy clamping. The connections permitted blood sampling and infusion. The body temperature was recorded continuously in the abdominal cavity.
The heart donors wer anaesthetized with ether. After 200 IU of heparin intravenously the blood was rapidly collected from the abdominal aorta. Subsequent thoracotomy and ligation of the aortic arch branches, the heart-archpreparation was excised. The time required for this pro
cedure was 3 - 5 minutes.
The ascending aorta was attached to the ccinnula from the supporting rat. Electrodes for ECG-recording were placed at the apex, the right atrium and the aortic arch. During the ischemic period, the heart was kept in a water-jacketed funnel filled with plain saline solution at 37 - 38ºC.
The retransfusion system consisted of a peristaltic roller pump (Mul ti perpl ex 2115 from LKB-Produkter AB, Bromma, Sweden), a temperature-controlled water bath and an air-bubble trap. All connections were of silicone rubber tubing. The system was primed with 20 ml of heparinized blood collected from the heart donor and an additional rat. The retransfusion of blood was adjusted to constant bloodpressure of the supporting rat by regulating the height of the bubble trap.
Normothermic ischemia was promoted by clamping the pump tube. After the ischemic period, the tube clamp was released and a pulsative blood-flow was re-established through the coronary arteries of the excised heart. All excised hearts were subjected to 15 minutes of complete global (37°C) ischemia, calculated from the time from excision of the heart to the start of reperfusion. Reperfusion with the pulsative arterial blood flow from the supporting rat was continued for 30 minutes, after which all hearts were immediately freeze-cl amped with a pair of chilled tongues (in liquid nitrogen) and transferred in liquid nitrogen. Freezing was instantaneous.
There was administred to a group of 11 excised rat hearts (group 1) through continuous perfusion simultaneously with the start of the reperfusion, 10 ml of physiological saline solution at room temperature through the pump tube. Perfusion was continued for seven minutes.
10 ml of solution according to Example 1 were administred to a further group of seven excised rat hearts (group 2) in the same manner as in group 1, by perfusion through the pump tube.
The following biochemical analyses were made:
Subsequent to being frozen, the excised hearts were stored at a temperature of -70ºC and then freeze-dried at a temperature beneath -4°C. Adenine-nucleotides and energy charge. were determined after perchloric acid extraction in the heart material using an HPLC-method (HPLC = High Performance Liquid Chromatography) . Thus, the analyses made it possible to accurately determine quantitatively the adenosine triphosphate (ATP), adenosi ne-diphosphate (ADP) and adenosi ne-monophosphate (AMP) enabling subsequent calculation of the energy charge (ACP, i.e. "adenylate charge potential") in accordance with the Atkinson equation (see Atkinson, D.E.: "The energy charge of the adenylate pool as a regulatory parameter. Interaction with feedback modifiers". Biochemistry 7 (1968) 4030-4038). The enzyme creatine kinase (CK) efflux was followed as an indicator of tissue damage. The principle for determining CK in serum was in accordance with recommendations from the Scandinavian Enzyme Committee, and the enzymatic activity was expressed in /ukat/l. (With respect to the HPLC-method applied, references were made to Hartwick, R.A. and Brown, P.R., "The performance of microparticle chemically bonded anionexchange. resins in the analysis of nucl eoti des.", J. Chromatog. 112 (1979) 651 - 660).
n = the number of hearts in the group.
The values are given as mean values - standard deviations . When making a comparison between group 1 (control group) and group 2 (treatment group) several important differences were found :
The difference in ACP is statistically significant
(p < 0.02) as are also the differences in ATP/ADP-ratio (p < 0.05) and the difference in the release of creatine kinase (as a measurement of cell-leakage) in the range of
20 - 30 minutes (p < 0.02).
In addition to the important biochemical differences shown in the table, the treated hearts in group 2 exhibited substantially improved contractibil ity when loaded than those in group 1, which had not been treated with the solution according to Example 1.
Claims
1. A pharmaceutical composition for preventing and treating ischemic cell damage, c h a r a c t e r i z e d i n that it contains a physiologically acceptable, water-soluble salt of phosphoenolpyruvic acid and a physiologically acceptable, water-soluble salt of adenosine 5' -triphosphoric acid in a mutual ratio of from 5:1 to 1000:1, preferably from 10:1 to 500:1, calculated on a molar basis.
2. A pharmaceutical composition according to Claim 1, c h a r a c t e r i z e d i n that it in addition, to the salts of phosphoenolpyruvic acid and of a adenosine-5'-triphosphoric acid comprises agents for establishing physiological conditions and, when necessary, water as a carrier.
3. A pharmaceutical composition according to Claim 1, c h a r a c t e r i z e d i n that it exists in a freeze-dried form or in the form of a sterile solution for parenteral administration.
4. A pharmaceutical composition according to Claim 1, c h a r a c t e r i z e d i n that it contains magnesium ions in a stoi chi ometri c relationship of about 1:1 in relation to adenosine tri phosphate.
5. A method of preventing and treating ischemic cell damage in mammals, including humans, or in organs excised therefrom, c h a r a c t e r i z e d b y administering to the mammal or to said organ a therapeutical ly effective dose of a pharmaceutical composition according to Claim 1.
6. A process for the preparation of a pharmaceutical composition for preventing and treating ischemic cell damage, c h a r a c t e r i z e d b y dissolving a physiologically acceptable water-soluble salt of phosphoenolpyruvic acid and a physiologically acceptable, watersoluble salt of adenosine-5'-triphosphoric acid in a mutual ratio of from 5:1 to 1000:1, preferably from 10:1 to 500:1, calculated on a molar basis, in a physiologically acceptable aqueous liquid, adjusting the pH of the solution as necessary with the aid of a base or an acid to obtain a physiologically acceptable pH, then sterilizing the solution and, when desired, freeze-drying the resultant solution,
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8200252A SE8200252L (en) | 1982-01-18 | 1982-01-18 | PHARMACEUTICAL COMPOSITION |
| SE8200252 | 1982-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0098853A1 true EP0098853A1 (en) | 1984-01-25 |
Family
ID=20345754
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP83900363A Withdrawn EP0098853A1 (en) | 1982-01-18 | 1983-01-14 | A pharmaceutical composition for preventing and treating ischemic cell damage and methods for the use and preparation thereof |
| EP83850004A Withdrawn EP0085033A1 (en) | 1982-01-18 | 1983-01-14 | A pharmaceutical composition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP83850004A Withdrawn EP0085033A1 (en) | 1982-01-18 | 1983-01-14 | A pharmaceutical composition |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP0098853A1 (en) |
| JP (1) | JPS58502208A (en) |
| DK (1) | DK421283D0 (en) |
| FI (1) | FI833320A (en) |
| NO (1) | NO833257L (en) |
| SE (1) | SE8200252L (en) |
| WO (1) | WO1983002391A1 (en) |
| ZA (1) | ZA83130B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8403912D0 (en) * | 1984-07-30 | 1984-07-30 | Pharmacia Ab | PHARMACEUTICAL KIT OR COMPOSITION |
| US4874882A (en) * | 1986-03-25 | 1989-10-17 | Ube Industries, Ltd. | Process for preparing monosodium phosphoenolpyruvate |
| WO1988002258A1 (en) * | 1986-10-06 | 1988-04-07 | The University Of Virginia Alumni Patents Foundati | Use of an adenosine, hypoxanthine and ribose-containing solution for improved protection of the heart during surgery |
| US5070877A (en) * | 1988-08-11 | 1991-12-10 | Medco Research, Inc. | Novel method of myocardial imaging |
| JP2770175B2 (en) * | 1988-09-27 | 1998-06-25 | 科学技術振興事業団 | Kidney protective liquid |
| JP2914454B2 (en) * | 1989-03-29 | 1999-06-28 | メドコー・リサーチ・インコーポレイテッド | Vascular diagnostic aid |
| FR2684381B1 (en) * | 1991-12-03 | 1995-05-05 | Nicole Bru | COMPOUNDS HAVING A PHOSPHORIC AMIDE LINK OR AN ENOL PHOSPHATE LINK FOR THEIR APPLICATION AS A THERAPEUTICALLY ACTIVE SUBSTANCE. |
| DE19603053A1 (en) * | 1996-01-29 | 1997-07-31 | Bayer Ag | Process for the preparation of polymers with repeating succinyl units |
| GB9624188D0 (en) | 1996-11-21 | 1997-01-08 | Itc Research Limited | Pharmaceutical formulations |
| CN101511376A (en) * | 2006-09-28 | 2009-08-19 | 兴和株式会社 | Cardiovascular preparation |
| TW200824676A (en) * | 2006-10-24 | 2008-06-16 | Kowa Co | Cardiovascular drug |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1083911A (en) * | 1964-01-13 | 1967-09-20 | Chugai Pharmaceutical Co Ltd | Adenosine triphosphate salts of l-ornithine and process for preparing the same |
| FR3246M (en) * | 1964-02-06 | 1965-04-12 | Pharmacodynamie Et Metabolisme | Medicines based on phospho-enol-pyruvic acid. |
| DE1939008A1 (en) * | 1969-07-31 | 1971-02-11 | Zander Dr Helmut | Curing disturbances in brain functioning - caused by defective blood circulation |
| US4216211A (en) * | 1977-10-31 | 1980-08-05 | The Procter & Gamble Company | Therapeutic composition |
-
1982
- 1982-01-18 SE SE8200252A patent/SE8200252L/en not_active Application Discontinuation
-
1983
- 1983-01-10 ZA ZA83130A patent/ZA83130B/en unknown
- 1983-01-14 EP EP83900363A patent/EP0098853A1/en not_active Withdrawn
- 1983-01-14 JP JP83500392A patent/JPS58502208A/en active Pending
- 1983-01-14 WO PCT/SE1983/000003 patent/WO1983002391A1/en active Application Filing
- 1983-01-14 EP EP83850004A patent/EP0085033A1/en not_active Withdrawn
- 1983-09-12 NO NO833257A patent/NO833257L/en unknown
- 1983-09-15 DK DK4212/83A patent/DK421283D0/en not_active Application Discontinuation
- 1983-09-16 FI FI833320A patent/FI833320A/en not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO8302391A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DK421283A (en) | 1983-09-15 |
| JPS58502208A (en) | 1983-12-22 |
| EP0085033A1 (en) | 1983-08-03 |
| FI833320A0 (en) | 1983-09-16 |
| WO1983002391A1 (en) | 1983-07-21 |
| SE8200252L (en) | 1983-07-19 |
| DK421283D0 (en) | 1983-09-15 |
| FI833320A (en) | 1983-09-16 |
| NO833257L (en) | 1983-09-12 |
| ZA83130B (en) | 1983-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4605644A (en) | Method for stimulating recovery from ischemia employing ribose and adenine | |
| Soltoff | ATP and the regulation of renal cell function | |
| Ely et al. | Functional and metabolic evidence of enhanced myocardial tolerance to ischemia and reperfusion with adenosine | |
| US5091404A (en) | Method for restoring functionality in muscle tissue | |
| Perry et al. | Ischemia: Profile of an enemy: Reperfusion injury of skeletal muscle | |
| Opperdoes et al. | Trypanosoma brucei: an evaluation of salicylhydroxamic acid as a trypanocidal drug | |
| Rider et al. | Production of Tolerance in the Rat to Octamethyl Pyrophosphoramide (OMPA). | |
| US6986905B1 (en) | Pharmaceutical compositions for treating and saving and the method for the preparation thereof | |
| EP0098853A1 (en) | A pharmaceutical composition for preventing and treating ischemic cell damage and methods for the use and preparation thereof | |
| JPH02111724A (en) | Drug for increasing adenosine 5'-triphosphate level in blood and plasma containing adenine nucleotide as effective component | |
| Barrett et al. | Hepatic and extrahepatic splanchnic glucose metabolism in the postabsorptive and glucose fed dog | |
| EP0590514A1 (en) | Blood preserving composition and method for preserving blood | |
| Beard et al. | The treatment of deep mycotic infections with amphotericin B: with particular emphasis on drug toxicity | |
| CN101282741A (en) | Method for treating or preventing ischemia reperfusion injury or multi-organ failure | |
| Solomon et al. | In vivo effect of volume expansion on rectal gland function. I. Humoral factors | |
| Hasselgren et al. | Failure of an increased dose of ATP-MgCl2 to improve protein synthesis and transmembrane potential in the postischemic liver | |
| JP3102945B2 (en) | Hepatitis treatment | |
| JP2974740B2 (en) | Agent for increasing liver, blood and plasma adenosine 5'-triphosphate concentration | |
| Sitprija et al. | Isoniazid intoxication | |
| Raoof et al. | Lithium inhibits human sperm motility in vitro. | |
| Yamagishi et al. | Effects of three purine‐related compounds on pancreatic exocrine secretion in the dog | |
| Zlokovic et al. | An in situ perfused guinea-pig eye model for blood-ocular transport studies: application to amino acids | |
| EP0665016A1 (en) | Heart function restorative | |
| Tygstrup | Aspects of hepatic hypoxia: observations on the isolated, perfused pig liver. | |
| Rao et al. | Effects of metabolic stimulation on cardiac allograft recovery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB LI LU NL SE |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PHARMACIA AB |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19840329 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HULTMAN, JAN LENNART Inventor name: RONQUIST, GUNNAR |